Heron Therapeutics
HRTX
164 hedge funds and large institutions have $274M invested in Heron Therapeutics in 2025 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 18 closing their positions.
2,362% more call options, than puts
Call options by funds: $4.21M | Put options by funds: $171K
56% more capital invested
Capital invested by funds: $176M → $274M (+$98.7M)
33% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 18
6.34% more ownership
Funds ownership: 75.57% → 81.91% (+6.3%)
2% more funds holding
Funds holding: 161 → 164 (+3)
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.74M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.39M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.3M |
| 4 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
+$2.64M |
| 5 |
Millennium Management
New York
|
+$2.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.67M |
| 2 |
CC
Clearline Capital
New York
|
-$1.46M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.43M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.26M |
| 5 |
OCM
Orchard Capital Management
Chicago,
Illinois
|
-$863K |
HRTX Hedge Fund Activity: Q1 2025 in Review
164 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2025, worth a combined $274M — up 56% from $176M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new HRTX positions and 18 closed out — a net gain of 6 holders — while 50 added to existing stakes and 46 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $5.74M. The largest seller was Morgan Stanley, cutting an estimated $1.67M.
- 164 institutional investors held Heron Therapeutics (HRTX) as of Q1 2025, up from 161 in Q4 2024.
- Funds reported $274M of Heron Therapeutics stock for Q1 2025, up 56% quarter-over-quarter.
- 24 funds opened new Heron Therapeutics positions in Q1 2025 and 18 closed out, a net change of +6 holders.
- The largest Heron Therapeutics buyer in Q1 2025 was T. Rowe Price Associates, an estimated $5.74M added.
- The largest Heron Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $1.67M sold.
Based on aggregated 13F filings for Q1 2025.